Roche has its Cake--and Eats it
Roche has always been a strategic trailblazer--both in acquiring a biotech and now spinning it off. Genentech's employees are delighted and Roche, with its IPO of Genentech shares, may have hit on a way of both financing its buyback of Genentech's stock and keeping its key scientists motivated.
You may also be interested in...
Roche Diagnostics is the best performing asset at Roche. As the troubled Swiss pharma company suffers through its worst pipeline drought in a decade, Roche Diagnostics is delivering a stellar performance. It is strong across all business segments, from laboratory systems to diabetes to molecular testing. Its challenge: to pull far enough ahead in its traditional businesses to maintain a comfortable lead. Its bigger hurdle, however, is to position itself as a leader in adoption of new genomic and proteomic diagnostic technologies, which is where the industry's future growth lies.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.